Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Medicaid coverage is determined by individual states, so while some states have begun covering GLP-1s for obesity treatment, others continue to limit their use to diabetes management
Lilly has signaled its plans to submit tirzepatide to the FDA, potentially leading to competition between tirzepatide and semaglutide in the obesity and type 2 diabetes treatment markets
Read on to learn what you need to know
It's a percentage
This was not a fringe decision from a single insurer
US$ 29.09
US$ 24.15
US$ 24.87
US$ 21.81
US$ 26.08
